NCT07107802View on ClinicalTrials.gov

Phase 1 Single Ascending Dose Study With ATX101

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 19, 2025

Primary Completion Date

November 14, 2025

Study Completion Date

November 14, 2025

Conditions
Healthy Participants
Interventions
DRUG

ATX101

Single intravenous dose

DRUG

Placebo

Single intravenous dose

Trial Locations (1)

4250-449

RECRUITING

BlueClinical Phase I, Porto

Sponsors
All Listed Sponsors
lead

Aurobac Therapeutics SAS

INDUSTRY

NCT07107802 - Phase 1 Single Ascending Dose Study With ATX101 | Biotech Hunter | Biotech Hunter